A recent multicenter study by Molinaro et al.59 clarified this by demonstrating improved OS associated with maximal resection of contrast-enhanced tumor, regardless of isocitrate dehydrogenase 1 or 2 gene (IDH)-wild or IDH-mutant subtype and methylation status of the promoter region of the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT).60 In fact, in younger patients below the age of 65 years, surgical resection of even the non-contrast-enhancing disease was shown to confer a greater survival benefit. The gene discussed is MGMT; the disease is neoplasm.